Drug Information

Drug General Information
Drug ID
D0L7LH
Former ID
DIB013007
Drug Name
Anti-IP10
Drug Type
Antibody
Indication Crohn's disease; Ulcerative colitis [ICD9: 555, 556, 556.9; ICD10:K50, K50-K52, K51] Phase 2 [523682]
Company
Bristol-myers squibb
Target and Pathway
Target(s) Small inducible cytokine B10 Target Info [532252]
KEGG Pathway Cytokine-cytokine receptor interaction
Chemokine signaling pathway
Toll-like receptor signaling pathway
RIG-I-like receptor signaling pathway
Cytosolic DNA-sensing pathway
TNF signaling pathway
Influenza A
NetPath Pathway IL-7 Signaling Pathway
TSLP Signaling Pathway
TNFalpha Signaling Pathway
TWEAK Signaling Pathway
TCR Signaling Pathway
PANTHER Pathway Inflammation mediated by chemokine and cytokine signaling pathway
Pathway Interaction Database CXCR3-mediated signaling events
Reactome Chemokine receptors bind chemokines
G alpha (i) signalling events
WikiPathways Toll-like receptor signaling pathway
Type II interferon signaling (IFNG)
Spinal Cord Injury
GPCR ligand binding
GPCR downstream signaling
Regulation of toll-like receptor signaling pathway
References
Ref 523682ClinicalTrials.gov (NCT01466374) Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease. U.S. National Institutes of Health.
Ref 532252Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study. Gut. 2014 Mar;63(3):442-50.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.